34914-36-8

Basic information

• Product Name: Acetic acid, [(triphenylmethyl)thio]-
• CAS NO: 34914-36-8
• Molecular Formula: C21H18O2S
• Molecular Weight: 334.439
• Mol File: 34914-36-8.mol
• Article Data: 23

Chemical Properties

• CAS DataBase Reference: Acetic acid, [(triphenylmethyl)thio]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, [(triphenylmethyl)thio]-(34914-36-8)
• EPA Substance Registry System: Acetic acid, [(triphenylmethyl)thio]-(34914-36-8)

Safety Data

• Hazardous Substances Data: 34914-36-8(Hazardous Substances Data)

Usage

General Description

Acetic acid, [(triphenylmethyl)thio]-, also known as triphenylmethanethiol, is a chemical compound with the molecular formula C21H18OS. It is a clear to light yellow liquid with a pungent odor and is commonly used as a building block in organic synthesis. It is also used in the production of dyes, pharmaceuticals, and agrochemicals. Triphenylmethanethiol is known to be an irritant to the skin, eyes, and respiratory system and should be handled with proper protective equipment and caution. It is important to follow all safety guidelines and regulations when working with this chemical.

Upstream product

• 3926-62-3 sodium monochloroacetic acid 
• 76-83-5 trityl chloride 
• 68-11-1 mercaptoacetic acid 
• 968-39-8 Triphenylmethylethylether 
• 886983-43-3 ethyl 3-{2-[(triphenylmethylsulfanyl)methylcarbonylamino]ethanamido}-4-hydroxybenzoate 
• 83544-05-2 triphenylmethyl thioglycolic acid methyl ester 
• 76-84-6 triphenylmethyl alcohol 
• 3695-77-0 triphenylmethanethiol 
• 79-08-3 bromoacetic acid 
• 29167-19-9 tritylmercapto-acetic acid ethyl ester 

Downstream Products

• 29167-19-9 tritylmercapto-acetic acid ethyl ester 
• 131102-50-6 C₄₇H₃₉NO₈S 
• 166169-07-9 N-methoxy-N-methyl-2-(tritylthio)acetamide 
• 355127-53-6 N-(S-trityl-2-mercaptoacetyl)-3-aminopropanol 
• 521935-97-7 N-phenyl-2-tritylsulfanyl-acetamide 
• 460077-69-4 4-(tritylmercaptoacetamide)phenyl α-D-galactopyranoside 
• 944457-67-4 6-(2-tritylsulfanyl-acetylamino)hexanoic acid benzyl ester 
• 852619-78-4 N-quinolin-3-yl-3-(2-tritylsulfanyl-acetylamino)-propionamide 
• 852619-79-5 N-quinolin-3-yl-4-(2-tritylsulfanyl-acetylamino)-butyramide 
• 852619-80-8 5-(2-tritylsulfanyl-acetylamino)-pentanoic acid quinolin-3-ylamide 
• 852619-81-9 6-(2-tritylsulfanyl-acetylamino)-hexanoic acid quinolin-3-ylamide 
• 944412-76-4 C₅₄H₅₄N₂O₁₃S 
• 944412-75-3 6-(3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(allyloxy)-4-oxobutan-2-yloxy)-2-(acetoxymethyl)-5-(2-(tritylthio)acetamido)tetrahydro-2H-pyran-3,4-diyl diacetate 
• 1021342-87-9 C₃₅H₅₄N₁₀O₁₂S 

Relevant articles and documents

Ribosomal Synthesis of Backbone-Cyclic Peptides Compatible with in Vitro Display

Backbone-cyclic peptides are an attractive class for therapeutic development. However, in vitro display technologies coupled with ribosomal synthesis are intrinsically inapplicable to such "phenotypes" because of loss of the C-terminal peptide region linking to "genotype". Here, we report a methodology enabling the display of backbone-cyclic peptides. To achieve this, genetic code reprogramming was utilized to implement a rearrangement strategy involving the ribosomal incorporation of a designer initiator containing a thiazolidine-protected cysteine and 2-chloroacetoamide (ClAc) side chain, followed by an α-thio acid and cysteine at downstream positions. Upon expression of the linear peptide, spontaneous thioester rearrangement occurs between the α-thioester and the thiol group of the cysteine, liberating the α-thio group and resulting in cross-linking to the upstream ClAc side-chain group. Then selective deprotection of the thiazolidine-protected cysteine immediately promotes intramolecular native chemical ligation, as demonstrated for various sequences and ring sizes. In this approach, the backbone-cyclic peptides retain their C-terminal peptide regions via the side-chain thioether covalent linkage, making them compatible with in vitro display.

Synthesis of functionalized amides of 2-(arylamino)pyrimidine series

New amides of 2-(arylamino)pyrimidine series were synthesized with pharmacophoric fragments of tyrosine kinase and histone deacetylase inhibitors and functional groups providing chemosorption of compounds on nanocarriers.

RADIOTRACER PRECURSOR BANI FOR IMAGING OF HYPOXIC TISSUE, RADIOTRACER, AND METHOD FOR PREPARING THE SAME

The present invention relates to a radiotracer precursor for imaging of hypoxic tissues, a radiotracer and a method for preparing the same. The radiotracer precursor, BANI, includes a nitroimidazole functional group with a feature of retention in hypoxic